Literature DB >> 9168506

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

B Frederiksen1, C Koch, N Høiby.   

Abstract

Chronic pulmonary infection with Pseudomonas aeruginosa (PA) develops in most patients with cystic fibrosis (CF) and is associated with a poor prognosis. Much effort has been directed toward treating the chronic infection, but it is almost impossible to eradicate it once established; therefore, prevention is preferable. Since 1989 CF patients at the Danish CF Center in Copenhagen have been treated with an intensive three-step-protocol consisting of colistin inhalations and oral ciprofloxacin at the time of initial PA colonization. This study compares 48 patients treated according to this intensive protocol with 43 historic controls. The study was carried out over 44 months and included 218 patient-years. Only 16% of the treated patients developed chronic PA infection after 3 1/2 years compared with 72% of the control patients (Kaplan Meier estimate, P < 0.005, log rank test). This indicates that aggressive treatment prevented or delayed chronic PA infection in 78% of the patients for 3 1/2 years. Furthermore, aggressive treatment maintained or increased pulmonary function (forced vital capacity and forced expiratory volume in 1 second in percent of predicted values) during the year after inclusion compared with the control group, in which pulmonary function declined (P < 0.01, Mann-Whitney test). Although some of the treated patients eventually developed chronic PA infection, these patients had significantly better pulmonary function at the onset of chronic PA infection compared with control patients (P < 0.001, Mann-Whitney test). When the different steps in the intensive three-step-protocol were analyzed, there was a trend suggesting that 3 months of high-dose treatment with colistin inhalation and oral ciprofloxacin produced the best results in terms of postponement or prevention of chronic PA infection (P < 0.05).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168506     DOI: 10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  109 in total

Review 1.  Cystic fibrosis.

Authors:  P Robinson
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

2.  Is prolonged rotavirus infection a common cause of protracted diarrhoea?

Authors:  M Sood; I W Booth
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

3.  Evidence for using nebulised antibiotics in cystic fibrosis.

Authors:  S P Conway
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

Review 4.  Ethical aspects of using radiolabelling in aerosol research.

Authors:  M L Everard
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

Review 5.  Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Authors:  Melissa B Miller; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

Review 6.  Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp.

Authors:  Andrew M Jones; A Kevin Webb
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 7.  Macrolides in the respiratory tract in cystic fibrosis.

Authors:  Adam Jaffé; Mark Rosenthal
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

8.  Sound waves effectively assist tobramycin in elimination of Pseudomonas aeruginosa biofilms in vitro.

Authors:  H M H N Bandara; A Harb; D Kolacny; P Martins; H D C Smyth
Journal:  AAPS PharmSciTech       Date:  2014-08-26       Impact factor: 3.246

9.  Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas aeruginosa.

Authors:  Tim Holm Jakobsen; Steinn Kristinn Bragason; Richard Kerry Phipps; Louise Dahl Christensen; Maria van Gennip; Morten Alhede; Mette Skindersoe; Thomas Ostenfeld Larsen; Niels Høiby; Thomas Bjarnsholt; Michael Givskov
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

Review 10.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.